Patients with B and C stages according to the 2022 Barcelona Clinic Liver Cancer (BCLC) staging system
Conditions
Interventions
Patients with B and C stages according to the 2022 update of the Barcelona Clinic Liver Cancer (BCLC) staging system:without involving
Sponsors
Affiliated Hospital of Chengdu University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 18–80 years, both genders eligible; 1.Pathologically or cytologically confirmed hepatocellular carcinoma (HCC), with BCLC stage B or C according to the 2022 guidelines; 2.Ability to obtain sufficient fresh tumor tissue (via surgical resection or biopsy) and autologous PBMCs (peripheral blood mononuclear cells) for organoid establishment; 3.ECOG Performance Status: 0–2; 4.No prior systemic first-line antitumor therapies (e.g., targeted agents, immunotherapies) administered before surgical intervention; 5.Voluntary participation with signed informed consent form (ICF), demonstrating compliance and willingness to adhere to follow-up protocols;
Exclusion criteria
Exclusion criteria: 1.Patients with other concurrent malignant tumors; 2.Patients who have undergone liver transplantation; 3.Immunocompromised patients with active infections in other anatomical sites; 4.Patients with severe hepatorenal diseases, cardiovascular diseases, hematologic disorders, or other comorbidities; 5.Patients who have received first-line systemic antitumor therapies or other treatments prior to the initial tissue sampling; 6.Judged by the investigators to be unsuitable for participation in this study;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Generational stability;Drug Resistance Index;DEGs Screening; | — |
Countries
China
Contacts
Public ContactXiangke Niu
Affiliated Hospital of Chengdu University
Outcome results
None listed